Biologic therapies for adult chronic urticaria: what works, what doesn't, and why. (PubMed, Expert Opin Biol Ther) - Sep 24, 2026 - "Omalizumab remains the benchmark therapeutic agent. Dupilumab inhibits interleukin-4/interleukin-13 signaling and is approved for CSU and several type 2 and other inflammatory conditions. Remibrutinib is an oral Bruton tyrosine kinase inhibitor with efficacy across IgE-defined subgroups, supporting its relevance beyond a single proposed autoimmune endotype...Biomarkers should inform response probabilities rather than rigid prescribing decisions. Definitive disease modification remains unproven."
Journal • Review • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria • IL13 • IL4
|
|
Aist? Ramanauskait?; Emek Kocatürk; Muhammed Burak Yücel; Murat Türk; Yi-Kui Xiang; Zenon Brzoza
|